Efficacy of almitrine-raubasine in cognitive disorders of aging: a double-blind, placebo-controlled, clinical and psychometric study.

Abstract

Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001).

• Authors: P U Carbonin, A Greco, P Pisanti, A Gemma, F Cattelin
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) Vol. 13 Suppl 3 Pg. S92-9 ( 1990) ISSN: 0362-5664 [Print] United States
• PMID: 2093422 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Combinations
• Secologanin Tryptamine Alkaloids
• Yohimbine
• raubasine
• Almitrine

Topics

• Aged
• Aged, 80 and over
• Aging (psychology)
• Almitrine (therapeutic use)
• Cognition Disorders (drug therapy)
• Double-Blind Method
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Psychological Tests
• Psychometrics
• Secologanin Tryptamine Alkaloids
• Yohimbine (analogs & derivatives, therapeutic use)